Chapter title |
Emerging Antibody-based Products
|
---|---|
Chapter number | 240 |
Book title |
Plant Viral Vectors
|
Published in |
Current topics in microbiology and immunology, July 2012
|
DOI | 10.1007/82_2012_240 |
Pubmed ID | |
Book ISBNs |
978-3-64-240828-1, 978-3-64-240829-8
|
Authors |
Kevin J. Whaley, Josh Morton, Steve Hume, Ernie Hiatt, Barry Bratcher, Victor Klimyuk, Andrew Hiatt, Michael Pauly, Larry Zeitlin, Whaley, Kevin J., Morton, Josh, Hume, Steve, Hiatt, Ernie, Bratcher, Barry, Klimyuk, Victor, Hiatt, Andrew, Pauly, Michael, Zeitlin, Larry |
Abstract |
Antibody-based products are not widely available to address many global health challenges due to high costs, limited manufacturing capacity, and long manufacturing lead times. There are now tremendous opportunities to address these industrialization challenges as a result of revolutionary advances in plant virus-based transient expression. This review focuses on some antibody-based products that are in preclinical and clinical development, and have scaled up manufacturing and purification (mg of purified mAb/kg of biomass). Plant virus-based antibody products provide lower upfront cost, shorter time to clinical and market supply, and lower cost of goods (COGs). Further, some plant virus-based mAbs may provide improvements in pharmacokinetics, safety and efficacy. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 16 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 4 | 25% |
Student > Master | 2 | 13% |
Professor > Associate Professor | 2 | 13% |
Researcher | 2 | 13% |
Student > Bachelor | 2 | 13% |
Other | 3 | 19% |
Unknown | 1 | 6% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 4 | 25% |
Medicine and Dentistry | 3 | 19% |
Biochemistry, Genetics and Molecular Biology | 3 | 19% |
Chemical Engineering | 2 | 13% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
Other | 2 | 13% |